UK Markets closed

Bionano Genomics, Inc. (BNGO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.10-0.10 (-1.53%)
As of 3:58PM EDT. Market open.

Bionano Genomics, Inc.

9540 Towne Centre Drive
Suite 100
San Diego, CA 92121
United States
858 888 7600

IndustryDiagnostics & Research
Full-time employees147

Key executives

NameTitlePayExercisedYear born
Dr. Robert Erik HolmlinPres, CEO, Sec. & Director519.07kN/A1968
Mr. Christopher P. StewartChief Financial Officer77.93kN/A1970
Mr. Mark OldakowskiChief Operating Officer376.1kN/A1974
Dr. Alka Chaubey FACMG, Ph.D.Chief Medical OfficerN/AN/A1973
Mr. Robert J. PriarChief Commercial OfficerN/AN/AN/A
Mr. Richard ShippyChief Bus. OfficerN/AN/AN/A
Mark AdamchakControllerN/AN/AN/A
Dr. Paul R. Selvin Ph.D.Scientific AdvisorN/AN/AN/A
Prof. Pui-Yan KwokScientific AdvisorN/AN/AN/A
Dr. Charles Lee Ph.D.Scientific AdvisorN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Corporate governance

Bionano Genomics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.